Objective To analyze Wu Zihui's medication rules for treating insomnia through data mining technology.Methods A total of 131 medical cases diagnosed with insomnia and admitted to the Outpatient Department of Wu Zihui at the International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine from June 2020 to March 2024 were sorted out.After standardizing the entered medical case data using the Gujin Medical Case Cloud Platform V2.3.9,statistical analysis,cluster analysis and complex network analysis of the prescription drugs were conducted respectively to summarize the experience of prescription drug use and the rules of formula composition.Results A total of 131 medical cases involved 143 traditional Chinese medicines.It was concluded that the properties were mainly cold and neutral,the flavors were mainly sweet and bitter,the meridians were mainly liver and heart meridians,and high-frequency drugs,Baishao Baizhu,Nyuzhenzi etc.Cluster analysis yielded 5 clustering prescriptions.Complex network analysis of traditional Chinese medicine syndrome types and drugs can result in two core traditional Chinese medicine prescriptions for insomnia syndrome.Conclusion In the treatment of insomnia,attention should be paid to the treatment of heart,liver,spleen and kidney.The treatment principle should be to relieve liver depression,clear heat and purge fire,nourish heart and calm the mind,and supplement spleen and kidney.

Objective To analyze Wu Zihui's medication rules for treating insomnia through data mining technology.Methods A total of 131 medical cases diagnosed with insomnia and admitted to the Outpatient Department of Wu Zihui at the International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine from June 2020 to March 2024 were sorted out.After standardizing the entered medical case data using the Gujin Medical Case Cloud Platform V2.3.9,statistical analysis,cluster analysis and complex network analysis of the prescription drugs were conducted respectively to summarize the experience of prescription drug use and the rules of formula composition.Results A total of 131 medical cases involved 143 traditional Chinese medicines.It was concluded that the properties were mainly cold and neutral,the flavors were mainly sweet and bitter,the meridians were mainly liver and heart meridians,and high-frequency drugs,Baishao Baizhu,Nyuzhenzi etc.Cluster analysis yielded 5 clustering prescriptions.Complex network analysis of traditional Chinese medicine syndrome types and drugs can result in two core traditional Chinese medicine prescriptions for insomnia syndrome.Conclusion In the treatment of insomnia,attention should be paid to the treatment of heart,liver,spleen and kidney.The treatment principle should be to relieve liver depression,clear heat and purge fire,nourish heart and calm the mind,and supplement spleen and kidney.

Objective To search for the reports of adverse events of levofloxacin use in children using the FAERS database,and to mine and analyze the data to provide reference for safe clinical use.Methods The data reported of adverse events of levofloxacin use in children from January 1,2004 to June 30,2023 were retrieved through the OpenVigil 2.1 platform,and the relevant data were analyzed based on the reporting odds ratio(ROR)method.Results A total of 484 cases of adverse events of levofloxacin in children were retrieved,and 94 positive risk signals were found.The main systemic organs involved were various musculoskeletal and connective tissues,gastrointestinal system,systemic and administration sites,and the top five positive signals were Dimycodes infection(ROR=822.87),tendon pain(ROR=563.71),Mycobacterium ulcers infection(ROR=352.65),tendon rupture(ROR=341.91),and immune reconstitution inflammatory syndrome-related tuberculosis(ROR=310.84).The top five positive signals not mentioned in the label were Mycobacterium ulcerans infection(ROR=352.65),immune reconstitution inflammatory syndrome-associated tuberculosis(ROR=310.84),central nervous system tuberculoma(ROR=102.85),linear IgA disease(ROR=82.68),and increased intracranial pressure(ROR=32.46).Conclusion In addition to the known adverse events,levofloxacin is used in children,and the risk signal intensity of adverse reactions such as increased intracranial pressure and tuberculosis-related diseases is high,so it is recommended to carefully select and strengthen relevant safety monitoring.

Objective:To evaluate the efficacy and safety of hybutimibe in the treatment of hypercholesterolemia.Methods:Relevant databases and clinical trial registration websites at home and abroad were searched (up to March 27, 2023), and randomized controlled trials (RCTs) of hybutimibe in the treatment of hypercholesterolemia have been collected. Patients in the trial group were given hybutimibe with or without other hypolipidemic agents, and those in the control group were given placebo or other hypolipidemic agents as same as that in the trial group. The primary outcome in effectiveness was the change rate of low-density lipoprotein cholesterol (LDL-C). The primary outcomes in safety were incidences of overall adverse events (AEs), serious AEs (SAEs), the trial termination due to AEs, and trial drug-related AEs. The secondary outcome in safety was incidence of the major AE reported in ≥ 2 trials. Meta-analysis was performed using RevMan 5.4 software. The effect sizes of counting data were expressed by the relative risk ( RR) and its 95% confidence interval ( CI). The effect sizes of measurement data were expressed by mean difference ( MD) and its 95% CI. Results:A total of 4 RCTs and 1 488 patients were entered in the analysis, including 952 patients in the trial group and 536 in the control group. The results of meta-analysis showed that at 8-12 weeks of treatment, the decrease rate of LDL-C in the trial group (hybutimibe 20 or 10 mg daily with or without atorvastatin 10 mg daily) was significantly greater than that in the control group (hybutimibe 20 mg daily: MD=-13.36%, 95% CI: -15.28% - -11.44%, P<0.001; hybutimibe 10 mg daily: MD=-10.80%, 95% CI: -14.90%- -6.71%, P<0.001); at 52 weeks of treatment, the average decrease rate (from baseline) of LDL-C in the trial group (hybutimibe 20 or 10 mg combined with atorvastatin 10 mg daily) was significantly greater than that in the control group with atorvastatin 10 mg daily monotherapy (-41.92% and -39.34% vs. -31.56%, all P<0.001); the incidences of overall AEs [47.94% (338/705) vs. 49.75% (202/406), RR=0.99, 95% CI: 0.87-1.12], SAEs[2.64% (16/606) vs. 2.79% (10/358), RR=1.19, 95% CI: 0.53-2.66], trial termination due to AEs[4.11% (29/705) vs. 4.68% (19/406), RR=0.67, 95% CI: 0.17-2.65], and trial drug-related AEs [12.38% (75/606) vs. 11.45% (41/358), RR=0.87, 95% CI: 0.37-2.06] were similar between the 2 groups at 8-12 weeks of treatment (all P>0.05). Conclusion:Hybutimibe could effectively reduce LDL-C level in patients with hypercholesterolemia, with good medication safety.

Along with the reforms of the assessment and approval regime for new drugs in China in recent years, independently researched and developed innovative drugs and conditionally approved drugs in China have been more and more. The pre-market clinical trials, assessment and approval system (especially the conditional approval system), and post-market monitoring and management of new drugs in China are still in a continuous improvement stage. Thus we need to specially pay attention to the safety of innovative drugs that independently developed in China and do a good job in post-marketing safety supervision. More evidence-based information for safe use of this type of medication in patients can be provided through the following aspects: strengthening the drug safety monitoring, conducting systematic evaluation of literature data, widely collecting drug safety data through high-quality real-world research, and conducting in-depth mining of information from drug safety reports.

Objective:To evaluate the efficacy and safety of hybutimibe in the treatment of hypercholesterolemia.Methods:Relevant databases and clinical trial registration websites at home and abroad were searched (up to March 27, 2023), and randomized controlled trials (RCTs) of hybutimibe in the treatment of hypercholesterolemia have been collected. Patients in the trial group were given hybutimibe with or without other hypolipidemic agents, and those in the control group were given placebo or other hypolipidemic agents as same as that in the trial group. The primary outcome in effectiveness was the change rate of low-density lipoprotein cholesterol (LDL-C). The primary outcomes in safety were incidences of overall adverse events (AEs), serious AEs (SAEs), the trial termination due to AEs, and trial drug-related AEs. The secondary outcome in safety was incidence of the major AE reported in ≥ 2 trials. Meta-analysis was performed using RevMan 5.4 software. The effect sizes of counting data were expressed by the relative risk ( RR) and its 95% confidence interval ( CI). The effect sizes of measurement data were expressed by mean difference ( MD) and its 95% CI. Results:A total of 4 RCTs and 1 488 patients were entered in the analysis, including 952 patients in the trial group and 536 in the control group. The results of meta-analysis showed that at 8-12 weeks of treatment, the decrease rate of LDL-C in the trial group (hybutimibe 20 or 10 mg daily with or without atorvastatin 10 mg daily) was significantly greater than that in the control group (hybutimibe 20 mg daily: MD=-13.36%, 95% CI: -15.28% - -11.44%, P<0.001; hybutimibe 10 mg daily: MD=-10.80%, 95% CI: -14.90%- -6.71%, P<0.001); at 52 weeks of treatment, the average decrease rate (from baseline) of LDL-C in the trial group (hybutimibe 20 or 10 mg combined with atorvastatin 10 mg daily) was significantly greater than that in the control group with atorvastatin 10 mg daily monotherapy (-41.92% and -39.34% vs. -31.56%, all P<0.001); the incidences of overall AEs [47.94% (338/705) vs. 49.75% (202/406), RR=0.99, 95% CI: 0.87-1.12], SAEs[2.64% (16/606) vs. 2.79% (10/358), RR=1.19, 95% CI: 0.53-2.66], trial termination due to AEs[4.11% (29/705) vs. 4.68% (19/406), RR=0.67, 95% CI: 0.17-2.65], and trial drug-related AEs [12.38% (75/606) vs. 11.45% (41/358), RR=0.87, 95% CI: 0.37-2.06] were similar between the 2 groups at 8-12 weeks of treatment (all P>0.05). Conclusion:Hybutimibe could effectively reduce LDL-C level in patients with hypercholesterolemia, with good medication safety.

Along with the reforms of the assessment and approval regime for new drugs in China in recent years, independently researched and developed innovative drugs and conditionally approved drugs in China have been more and more. The pre-market clinical trials, assessment and approval system (especially the conditional approval system), and post-market monitoring and management of new drugs in China are still in a continuous improvement stage. Thus we need to specially pay attention to the safety of innovative drugs that independently developed in China and do a good job in post-marketing safety supervision. More evidence-based information for safe use of this type of medication in patients can be provided through the following aspects: strengthening the drug safety monitoring, conducting systematic evaluation of literature data, widely collecting drug safety data through high-quality real-world research, and conducting in-depth mining of information from drug safety reports.

Objective: To understand the coincidence rate of adjustable and non adjustable desks and chairs in primary and secondary schools in Shanghai, so as to provide a reference for the effective management of desks and chairs in schools. Methods: Stratified random cluster sampling was applied to measure 1 091 sets of desks and chairs in 33 classrooms of 7 primary and secondary schools in 4 districts of Shanghai including Huangpu, Hongkou, Yangpu and Jiading districts. The height examination data of seated students in the same semester were also collected to evaluate the matching type of functional size of desks and chairs and students height according to Functional Sizes and Technical Requirements of Chairs and Tables for Educational Institutions. Results: The matching coincidence rate of desk and chair distribution in primary and secondary schools was 22.5%, and the matching coincidence rates of primary, middle and high schools were 11.7%, 27.1% and 40.9% respectively ( χ 2=83.23, P <0.01); the matching coincidence rate of adjustable desks and chairs (28.2%) was significantly higher than that of fixed (18.2%) ( χ 2=14.49, P <0.01). The type of distribution of desks and chairs that do not correspond to national standards, from elementary school to high school, showing a trend of high desks with high chairs, low desks with high chairs to high desks with low chairs. Conclusion The coincidence rate of desk and chair distribution in primary and secondary schools is low, and the adjustable desks and chairs has improved the problems to a certain extent, but has not significantly improved the coincidence rate. It is necessary to further explore the effective management mode in the use of adjustable desks and chairs and improve the current situation of the use of desks and chairs in schools.

ObjectiveTo investigate the application of Mengchao Liver Disease-Brain System version 2.0 in clinical diagnosis and treatment. MethodsThis study was conducted among 160 patients who were admitted to the internal medicine and surgical departments from June 9 to 21， 2021， and their data were automatically captured by the intelligent information system of Southeast Big Data Institute of Hepatobiliary Health， Mengchao Hepatobiliary Hospital of Fujian Medical University. The completeness and accuracy of Mengchao Liver Disease-Brain System version 2.0 were evaluated based on the intelligent diagnostic tools such as auxiliary diagnosis of chronic hepatitis B， interpretation of liver fibrosis， staging model of chronic hepatitis B， auxiliary diagnosis of liver cirrhosis， auxiliary staining of liver cirrhosis， auxiliary diagnosis of primary liver cancer， BCLC stage of primary liver cancer， Chinese staging of primary liver cancer， Child-Pugh score， and APRI score. ResultsAll auxiliary diagnostic tools had a complete rate of 94.17% in terms of the extraction of correct key dimensions within the test period. The artificial intelligence report had a structured accuracy of 97.55% in capturing data and an accuracy rate of 91.61% in text processing. ConclusionMengchao Liver Disease-Brain System version 2.0 provides an innovative mode for the construction of big data platform in medical specialties and has a high accuracy as an auxiliary diagnostic tool in clinical diagnosis and treatment.

Five new racemic N-acetyldopamine (NADA) trimers, asponchimides A-E (1-5), were isolated from Aspongopus chinensis, a prominent traditional Chinese medicinal insect employed for alleviating pain, treating indigestion, and addressing kidney ailments. Compounds 1-5 were successfully resolved by chiral high-performance liquid chromatography (HPLC), yielding five pairs of enantiomers: (+)- and (-)-asponchimides A-E (1a/1b-5a/5b). Their structural identities were discerned by extensive spectroscopic analyses, including high-resolution mass spectrometry (HRMS), ultraviolet-visible (UV-Vis) spectroscopy, infrared (IR) spectroscopy, and nuclear magnetic resonance (NMR), and their absolute configurations were determined by electronic circular dichroism (ECD) calculations. Compounds 1-5 are pioneering instances of NADA trimers featuring a Δ⁷ double bond. When subjected to a series of bioassays, a majority of the compounds exhibited weak inhibitory activity against nitric oxide (NO) production in LPS-induced RAW 264.7 cells.
Molecular Structure ; Magnetic Resonance Spectroscopy ; Dopamine ; Nitric Oxide